In recent generic drug news, the Food and Drug Administration approved a version of Kapvay, and Lupin has launched a version of the eye drug Zymaxid.
Par Pharmaceutical Cos. Oct. 7 announced that the Food and Drug Administration has approved its generic version of Concordia’s Kapvay (clonidine hydrochloride) 0.1 mg extended-release tablets.
Kapvay is indicated for treating attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
Par, which is based in Woodcliff Lake, N.J., said it has begun shipping the product.
Generic Zymaxid.
Lupin Ltd. Oct. 3 announced that its U.S. subsidiary, Lupin Pharmaceuticals Inc., ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.